Vaccinex announces completion of enrollment for SIGNAL Huntington’s disease trial

In June 2015, Vaccinex, the Huntington Study Group (HSG), and the University of Rochester’s Clinical Trials Coordination Center (CTCC) launched SIGNAL, the first clinical trial to investigate a

The post Vaccinex announces completion of enrollment for SIGNAL Huntington’s disease trial appeared first on Pharmaceutical Business review.

ADC Therapeutics announces first patient dosed in Phase I clinical trial of ADCT-601 in advanced solid tumors

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been

The post ADC Therapeutics announces first patient dosed in Phase I clinical trial of ADCT-601 in advanced solid tumors appeared first on Pharmaceutical Business review.

Acrotech to buy seven hematology/oncology products from Spectrum

Under the deal, Spectrum will secure $160m in an upfront cash payment, while up to $140m in regulatory and sales-based milestones. Spectrum Pharmaceuticals president and CEO Joe Turgeon

The post Acrotech to buy seven hematology/oncology products from Spectrum appeared first on Pharmaceutical Business review.

Schott to invest €300m in pharmaceutical packaging buisness

Through the investment, Schott plans to expand its primary business of glass tubing, used as the starting material for pharmaceutical packaging, and also pharmaceutical packaging made of glass and

The post Schott to invest €300m in pharmaceutical packaging buisness appeared first on Pharmaceutical Business review.

Janssen gets EC nod for prostate cancer drug Erleada

Erleada is a next generation oral androgen receptor inhibitor approved to treat adult patients with nmCRPC who are at high risk of developing metastatic disease. Apalutamide holds capacity

The post Janssen gets EC nod for prostate cancer drug Erleada appeared first on Pharmaceutical Business review.

Silence’s SLN124 gets orphan designation in Europe for β-Thalassemia

The designation to SLN124 was granted by the Committee for Orphan Medicinal Products (COMP), a committee of the European Medicines Agency (EMA). COMP after reviewing an application filed

The post Silence’s SLN124 gets orphan designation in Europe for β-Thalassemia appeared first on Pharmaceutical Business review.

Juvenescence closes first tranche of series B financing for further growth and development

Juvenescence intends to complete its $100 million Series B financing with the closing of a second tranche in Q1 2019. Juvenescence has now raised over $110 million in

The post Juvenescence closes first tranche of series B financing for further growth and development appeared first on Pharmaceutical Business review.

Luye Pharma grants AstraZeneca exclusive rights to promote Xuezhikang Capsules in mainland China

This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company.

The post Luye Pharma grants AstraZeneca exclusive rights to promote Xuezhikang Capsules in mainland China appeared first on Pharmaceutical Business review.

Sanofi to use Biomunex’s BiXAb platform to generate antibody therapeutics

As part of the deal, Sanofi will use the BiXAb platform of Biomunex to generate and enhance bi-specific and multi-specific antibodies. Sanofi will take responsibility for the research,

The post Sanofi to use Biomunex’s BiXAb platform to generate antibody therapeutics appeared first on Pharmaceutical Business review.

Bioharmony Therapeutics, Boehringer Ingelheim to advance bacteriophage lysin therapeutics to treat f multi-drug resistant bacterial infection

Bioharmony licensed this technology from the Rockefeller University. The discoveries are from the laboratory of Vincent A. Fischetti, Ph.D., a faculty member at The Rockefeller University. Recently, the

The post Bioharmony Therapeutics, Boehringer Ingelheim to advance bacteriophage lysin therapeutics to treat f multi-drug resistant bacterial infection appeared first on Pharmaceutical Business review.